Nanotechnology-based ocular drug delivery systems: recent advances and future prospects

S Li, L Chen, Y Fu - Journal of Nanobiotechnology, 2023 - Springer
Ocular drug delivery has constantly challenged ophthalmologists and drug delivery
scientists due to various anatomical and physiological barriers. Static and dynamic ocular …

Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations

S Sánchez-Ramón, L Conejero, MG Netea… - Frontiers in …, 2018 - frontiersin.org
Challenge with specific microbial stimuli induces long lasting epigenetic changes in innate
immune cells that result in their enhanced response to a second challenge by the same or …

Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy

Q Long, P Zheng, X Zheng, W Li, L Hua, Z Yang… - Advanced drug delivery …, 2022 - Elsevier
Bacterial membrane vesicles (BMVs) have emerged as novel and promising platforms for
the development of vaccines and immunotherapeutic strategies against infectious and …

Trained immunity: Target for prophylaxis and therapy

A Ziogas, M Bruno, R van der Meel, WJM Mulder… - Cell Host & Microbe, 2023 - cell.com
Trained immunity is a de facto memory for innate immune responses, leading to long-term
functional reprogramming of innate immune cells. In physiological conditions, trained …

[HTML][HTML] Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections

P Brandi, L Conejero, FJ Cueto, S Martínez-Cano… - Cell Reports, 2022 - cell.com
MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients
against recurrent respiratory infections, including those of viral etiology. However, its …

Sublingual MV140 for prevention of recurrent urinary tract infections

MF Lorenzo-Gómez, S Foley, JC Nickel… - NEJM …, 2022 - evidence.nejm.org
Background Recurrent urinary tract infections (UTIs), which consist of three or more
episodes in 1 year or two or more infections in 6 months, affect 5% to 10% of women …

Bacterial mucosal immunotherapy with MV130 prevents recurrent wheezing in children: a randomized, double-blind, placebo-controlled clinical trial

A Nieto, A Mazón, M Nieto, R Calderón… - American Journal of …, 2021 - atsjournals.org
Rationale: Recurrent wheezing in children represents a severe public health concern.
Wheezing attacks (WA), mainly associated with viral infections, lack effective preventive …

Promising immunomodulatory effects of bacterial lysates in allergic diseases

A Kaczynska, M Klosinska, K Janeczek… - Frontiers in …, 2022 - frontiersin.org
In light of an escalating prevalence of allergic disorders, it is crucial to fully comprehend their
pathophysiology and etiology. Such knowledge would play a pivotal role in the search for …

Toward prevention of childhood ALL by early-life immune training

J Hauer, U Fischer, A Borkhardt - Blood, The Journal of the …, 2021 - ashpublications.org
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common form of
childhood cancer. Chemotherapy is associated with life-long health sequelae and fails in∼ …

The bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity

C Del Fresno, J García-Arriaza… - Frontiers in …, 2021 - frontiersin.org
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus.
However, boosting innate responses may represent an innovative way to immediately fight …